| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 364.66 | 253.5 | 222.43 | 182.56 | 143.33 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 364.66 | 253.5 | 222.43 | 182.56 | 143.33 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 7.95 | 8.27 | 8.22 | 2.97 | 1.28 |
Total Income | 372.61 | 261.77 | 230.65 | 185.53 | 144.61 |
Total Expenditure | 267.45 | 202.5 | 165.81 | 130.71 | 99.94 |
PBIDT | 105.16 | 59.27 | 64.84 | 54.82 | 44.67 |
Interest | 6.62 | 5.44 | 6.72 | 7.83 | 12.41 |
PBDT | 98.54 | 53.83 | 58.12 | 46.99 | 32.26 |
Depreciation | 14.93 | 13.36 | 11.27 | 10.42 | 9.65 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 23.05 | 11.47 | 11.85 | 10.09 | 7.29 |
Deferred Tax | -0.93 | -1.03 | -0.95 | -0.6 | -0.46 |
Reported Profit After Tax | 61.49 | 30.03 | 35.95 | 27.08 | 15.78 |
Minority Interest After NP | -1.98 | -2.03 | -0.12 | 0.04 | 0.06 |
Net Profit after Minority Interest | 63.47 | 32.06 | 36.07 | 27.04 | 15.72 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 63.47 | 32.06 | 36.07 | 27.04 | 15.72 |
EPS (Unit Curr.) | 16.02 | 8.22 | 9.25 | 7.78 | 5.55 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 40.29 | 39 | 39 | 39 | 29.85 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 28.83 | 23.38 | 29.15 | 30.02 | 31.16 |
PBDTM(%) | 27.02 | 21.23 | 26.12 | 25.73 | 22.5 |
PATM(%) | 16.86 | 11.84 | 16.16 | 14.83 | 11 |
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.
The partnership is seeking to design and manufacture cutting-edge logistics and cargo drones for defence and civilian operations in the country.
EBITDA margins have increased considerably, at 26.2% in Q4 FY25, compared to 15.6% in the corresponding quarter of last year
Paras Defence will launch two models of advanced drone cameras, which sell for ₹20 lakh and ₹40 lakh per piece in the import market.
The project is expected to be operational in 2028.
The projected Optics Park is expected to cost over ₹12,000 Crore over 10 years, depending on land allotment and state government subsidies.
So far this year, this defence player's stock has increased by 42%, compared to a 10% increase in the benchmark Nifty 50.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
